-
-
-
-
-
-
-
Lilly to acquire Merida Biosciences to advance treatments for serious autoimmune and allergic diseases
-
-
-
-
-
-
-
Lilly to acquire AtaiBeckley to advance therapies for treatment-resistant depression and other mental health conditions
-
-
-
-
-
-
-
Lilly acquires three infectious disease companies for up to $3.83 billion
-
-
-
-
-
-
-
Lilly reports first-quarter 2026 financial results, raises full year guidance, and highlights momentum of new medicines
-
-
-
-
-
-
-
Lilly to acquire Kelonia Therapeutics to advance in vivo CAR-T cell therapies
-
-
-
-
-
-
-
Lilly to acquire Centessa Pharmaceuticals to advance treatments for sleep-wake disorders
-
-
-
-
-
-
-
Morgan Stanle on Eli Lilly (LLY): 'We see three potential scenarios for REDEFINE4'
-
1,200,048 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All


